FDA Approves CALQUENCE — AstraZeneca Pharmaceuticals LP

# FDA Approves AstraZeneca's CALQUENCE (acalabrutinib) for Blood Cancer Treatment AstraZeneca Pharmaceuticals LP received FDA approval for CALQUENCE (acalabrutinib), an oral Bruton's tyrosine kinase inhibitor, positioning the company to compete in the growing hematologic malignancy market dominated by BTK inhibitors. The approval expands AstraZeneca's oncology portfolio and provides physicians with a second-generation BTK inhibitor option that could capture market share from established competitors like Imbruvica.